



Integra LifeSciences Announces First Implantation of the HINTEGRA(R) Total Ankle Prosthesis in Brazil

PLAINSBORO, N.J., Feb. 10, 2005 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that the first three HINTEGRA® Total Ankle Prostheses, a product of Newdeal SA, have been implanted in Brazil. Brazil is the largest market for foot and ankle implants in South America, and has been a focus of Newdeal's efforts on that continent.

The HINTEGRA® Total Ankle Prosthesis is the first anatomical three-piece total ankle replacement. Newdeal has sold the product since 2000 in Europe, and since 2004 in Canada. More than 1,000 HINTEGRA® prostheses have been implanted. The device is not approved for sale in the United States.

The HINTEGRA® Total Ankle Prosthesis resurfaces the tibia and talus by minimal bone resection and incorporates a mobile inlay. The anatomical shape of the unique patented design of the HINTEGRA® Total Ankle Prosthesis provides high intrinsic stability, low contact stresses to the bone, low ligament stress and minimal wear.

"The HINTEGRA® Total Ankle Prosthesis is an elegant solution to the replacement of the ankle joint, and promises to make ankle replacement procedures attractive to more patients and their doctors," said Dr. Caio Nery, president of the Foot and Ankle Society of Brazil, and a Council Member of the International Federation of Foot and Ankle Societies, who implanted the prostheses. In October 2004, Dr. Nery organized a seminar in Sao Paulo on the application of the HINTEGRA® Total Ankle Prosthesis. Professor Beate Hintermann, inventor of the HINTEGRA® prosthesis, was the featured international speaker.

"The HINTEGRA® Total Ankle Prosthesis is an exciting part of our broad portfolio of products for the repair and reconstruction of the extremities," said Stuart M. Essig, President and Chief Executive Officer of Integra LifeSciences. "Newdeal's implants and instruments complement our soft tissue repair and regeneration products such as the NeuraGen™ Nerve Guide, the NeuraWrap™ Nerve Protector, the INTEGRA™ Bilayer Matrix Wound Dressing, and the INTEGRA™ Matrix Wound Dressing. Integra is also developing a product for the repair of tendons in the foot and ankle. Integra LifeSciences provides orthopedic and podiatric surgeons with a unique range of products that address most of the pathologies of the foot and ankle."

Newdeal, based in Lyon, France, is a leading developer and manufacturer of specialty implants and instruments specifically designed for foot and ankle surgery. Newdeal's products include a wide range of products for the forefoot, the mid-foot and the hind foot, including the Bold® Screw, the Hallu-Fix® plate system, the I.C.O.S. Compression Screw and the HINTEGRA® Total Ankle Prosthesis. The company sells its products through a direct sales force in France, Belgium and the Netherlands, and through distributors in more than 30 countries. Newdeal's target physicians include orthopedic surgeons specializing in injuries of the foot, ankle and extremities, and podiatric surgeons, of which there are 3,200 and 2,400, respectively, in the United States. Newdeal's current products address a worldwide market of approximately \$500 million.

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neuro-trauma and neurosurgery, reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have manufacturing and research facilities located throughout the world. We have approximately 1,200 employees. Please visit our website at (<http://www.Integra-LS.com>) and Newdeal's website at (<http://www.newdeal.info>).

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the HINTEGRA® Total Ankle Prosthesis. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, Integra's ability to secure regulatory approval and market acceptance for new products and to sell those products in international markets may affect actual results. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors That May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2003 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT:
Integra LifeSciences Holdings Corporation

John B. Henneman, III
Executive Vice President
Chief Administrative Officer
(609) 936-2481
jhenneman@Integra-LS.com

Maria Platsis
Director of Corporate Development
and Investor Relations
(609) 936-2333
mplatsis@Integra-LS.com